Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients
Juan Manuel Carreño(Icahn School of Medicine at Mount Sinai), Viviana Simon(Icahn School of Medicine at Mount Sinai), Fatima Amanat(Icahn School of Medicine at Mount Sinai), Komal Srivastava(Icahn School of Medicine at Mount Sinai), Harm van Bakel(Icahn School of Medicine at Mount Sinai), Hala Alshammary(Icahn School of Medicine at Mount Sinai), Ariel Raskin(Icahn School of Medicine at Mount Sinai), Ana S. Gonzalez‐Reiche(Icahn School of Medicine at Mount Sinai), Gagandeep Singh(Icahn School of Medicine at Mount Sinai), Florian Krammer(Semmelweis University), Emilia Mia Sordillo(Icahn School of Medicine at Mount Sinai), Adriana van de Guchte(Icahn School of Medicine at Mount Sinai), Angela A. Amoako(Icahn School of Medicine at Mount Sinai), D. Noah Sather(Center for Infectious Disease Research), PARIS study group(Icahn School of Medicine at Mount Sinai)
Cited by 55
Related Papers
Influenza
|Nature Reviews Disease Primers|2018|1.5k
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
|New England Journal of Medicine|2021|803